Pages

Cyclosporine beneficial in 82% of patients with severe chronic urticaria

The treatment of severe chronic urticaria (CU) remains a difficult goal to achieve. Many patients do not respond to anti-histamine therapy, even when off-label doses are given. Thus, cyclosporine-A (CsA) has been considered as therapeutic option for severe patients.

Among 2000 patients with CU who were referred to an outpatient clinic, 120 patients who suffered from a very severe CU began treatment with CsA 3 mg/kg.

In 20 patients, CsA was discontinued within 2-15 days after initiation because of side-effects.

Among 62 of the remaining 100 patients (62%), CsA was administered for a period of 3 months with a highly beneficial outcome.

In another 20 patients (20%), CsA was considered beneficial; however, it was required for a longer period of time, 5-10 years for some of the cases.

For 18 patients (18%), CsA therapy was reported as failed.

A low dose of CsA may be a good option for patients who suffer from especially severe CU.

Cyclosporine blocks T cell cytokine production by inhibiting activation of the NFAT transcription factor (note: different from NFkB).

Together with tacrolimus, cyclosporine is a calcineurin inhibitor (CNI). Initially isolated from a Norwegian soil sample, Ciclosporin A, the main form of the drug, is a cyclic peptide of 11 amino acids produced by the fungus Beauveria nivea.

Cyclosporin is thought to bind to the cytosolic protein cyclophilin (an immunophilin) of lymphocytes, especially T-lymphocytes. This complex of cyclosporin and cyclophilin inhibits calcineurin, which under normal circumstances induces the transcription of interleukin-2.

No comments:

Post a Comment

Total Pageviews

About Us

Disclaimer: All opinions expressed here are those of their authors and not of their employer. The information provided here is for educational purposes only and is not intended to provide medical advice. By accessing the web site, the visitors acknowledge that there is no physician-patient relationship between them and the authors.